Your session is about to expire
← Back to Search
Histamine H3 Receptor Antagonist
Double-Blind Treatment Period Pitolisant for Prader-Willi Syndrome
Phase 3
Recruiting
Research Sponsored by Harmony Biosciences, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to day 441
Awards & highlights
Study Summary
This trial is testing a medication called pitolisant to see if it can help patients with Prader-Willi syndrome who experience excessive daytime sleepiness. The study will also look at how pitolis
Who is the study for?
This trial is for patients aged 6 and older with Prader-Willi Syndrome, specifically to address excessive daytime sleepiness. Details about who can join or reasons for exclusion are not provided.Check my eligibility
What is being tested?
The study tests the effectiveness of a drug called Pitolisant compared to a placebo in reducing excessive daytime sleepiness in Prader-Willi Syndrome patients. It's randomized and double-blind, meaning neither participants nor researchers know who gets the real drug versus the placebo.See study design
What are the potential side effects?
Specific side effects of Pitolisant are not listed here, but common ones may include headache, insomnia, nausea, and irritability based on its use in treating other conditions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline up to day 441
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to day 441
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in severity of EDS as measured by Patient-Reported Outcomes Measurement Information System Bank v1.0 - Sleep-Related Impairment (PROMIS-SRI) T-score
Secondary outcome measures
Change in overall severity of EDS as measured by the Caregiver Global Impression of Severity for Excessive Daytime Sleepiness (CaGI-S for EDS)
Change in overall severity of EDS as measured by the Clinical Global Impression of Severity for Excessive Daytime Sleepiness (CGI-S for EDS)
Change in overall severity of irritable and disruptive behaviors as measured by the Caregiver Global Impression of Severity (CaGI-S) for Irritable and/or Disruptive Behaviors
+5 moreTrial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Open-Label Extension Period PitolisantExperimental Treatment1 Intervention
Pitolisant tablets administered once daily in the morning upon wakening
Group II: Double-Blind Treatment Period PitolisantExperimental Treatment1 Intervention
Pitolisant tablets administered once daily in the morning upon wakening
Group III: Double-Blind Treatment Period PlaceboPlacebo Group1 Intervention
Matching placebo administered tablets once daily in the morning upon wakening
Find a Location
Who is running the clinical trial?
Harmony Biosciences, LLCLead Sponsor
7 Previous Clinical Trials
1,784 Total Patients Enrolled
1 Trials studying Prader-Willi Syndrome
65 Patients Enrolled for Prader-Willi Syndrome
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the safety profile of pitolisant during the double-blind treatment phase for individuals?
"As a Phase 3 trial, the safety assessment for Double-Blind Treatment Period Pitolisant is rated as 3 by our team due to existing evidence of its effectiveness and robust safety data."
Answered by AI
Are there any available positions for patients in this ongoing clinical trial?
"Indeed, information found on clinicaltrials.gov reveals that this investigation is actively seeking volunteers. Initially shared on April 1st, 2024, and most recently revised on April 12th, 2024, the study aims to recruit 134 participants distributed across two locations."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger